Aktien Sensor

GE Healthcare has received FDA approval for an updated label on its positron emission tomography imaging agent, Vizamyl, allowing for more accurate and confident diagnoses of Alzheimer’s disease.

Dexcom’s stock price has surged due to the US government’s plans to promote wearable health monitoring systems nationwide, with analysts remaining optimistic about the company’s future prospects.

Veeva Systems has formed a strategic partnership with Grünenthal to streamline regulatory processes and accelerate the delivery of life-saving medicines to patients.

Philips is poised to capitalize on the shifting healthcare landscape, driven by a surge in demand for cutting-edge solutions due to an aging population and technological advancements.

Regeneron Pharmaceuticals has made significant strides with the launch of a donation matching program and FDA approval for Dupixent to treat bullous pemphigoid, solidifying its position as a leader in the pharmaceutical industry.

Gilead Sciences has made significant announcements, including a partnership to develop a novel cancer treatment, solidifying its position as a leader in innovative biopharmaceuticals.

Recordati Industria Chimica e Farmaceutica SpA has secured an exclusive licensing deal with Amarin to commercialize cardiovascular medicine Vazkepa in 59 European countries, marking a significant milestone for the company’s growth.

Centene Corp’s stock price may be stagnant, but the company is poised for growth as health insurers simplify prior authorization requests, a move that could boost customer satisfaction and loyalty.

Teva Pharmaceutical Industries Ltd has announced positive results from studies on its migraine prevention treatment, AJOVY, showing sustained effectiveness and a favorable safety profile over two years.

EssilorLuxottica’s stock price has taken a significant tumble, but despite a 10% year-over-year revenue growth and 15% year-over-year net income increase, investors are left wondering what’s behind the sudden downturn.